KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Operations: 2009-2024

Historic Cash from Operations for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to -$175.7 million.

  • Nektar Therapeutics' Cash from Operations fell 10.99% to -$48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.7 million, marking a year-over-year decrease of 7.46%. This contributed to the annual value of -$175.7 million for FY2024, which is 8.77% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Cash from Operations of -$175.7 million as of FY2024, which was up 8.77% from -$192.6 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Cash from Operations peaked at -$175.7 million during FY2024, and registered a low of -$412.7 million during FY2021.
  • For the 3-year period, Nektar Therapeutics' Cash from Operations averaged around -$224.1 million, with its median value being -$192.6 million (2023).
  • In the last 5 years, Nektar Therapeutics' Cash from Operations slumped by 31.72% in 2021 and then skyrocketed by 36.64% in 2023.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Cash from Operations stood at -$313.3 million in 2020, then slumped by 31.72% to -$412.7 million in 2021, then grew by 26.33% to -$304.0 million in 2022, then skyrocketed by 36.64% to -$192.6 million in 2023, then climbed by 8.77% to -$175.7 million in 2024.